Frerich Candace A, Brayer Kathryn J, Painter Brandon M, Kang Huining, Mitani Yoshitsugu, El-Naggar Adel K, Ness Scott A
Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.
Oncotarget. 2017 Dec 23;9(7):7341-7358. doi: 10.18632/oncotarget.23641. eCollection 2018 Jan 26.
The relative rarity of salivary gland adenoid cystic carcinoma (ACC) and its slow growing yet aggressive nature has complicated the development of molecular markers for patient stratification. To analyze molecular differences linked to the protracted disease course of ACC and metastases that form 5 or more years after diagnosis, detailed RNA-sequencing (RNA-seq) analysis was performed on 68 ACC tumor samples, starting with archived, formalin-fixed paraffin-embedded (FFPE) samples up to 25 years old, so that clinical outcomes were available. A statistical peak-finding approach was used to classify the tumors that expressed or , which had overlapping gene expression signatures, from a group that expressed neither oncogene and displayed a unique phenotype. Expression of or was closely correlated to the expression of the and genes, suggesting that they are direct targets of Myb proteins in ACC tumors. Unsupervised hierarchical clustering identified a subgroup of approximately 20% of patients with exceptionally poor overall survival (median less than 30 months) and a unique gene expression signature resembling embryonic stem cells. The results provide a strategy for stratifying ACC patients and identifying the high-risk, poor-outcome group that are candidates for personalized therapies.
涎腺腺样囊性癌(ACC)相对罕见,其生长缓慢但具有侵袭性,这使得用于患者分层的分子标志物的开发变得复杂。为了分析与ACC病程迁延及诊断后5年或更久出现转移相关的分子差异,对68例ACC肿瘤样本进行了详细的RNA测序(RNA-seq)分析,起始样本为存档的、长达25年的福尔马林固定石蜡包埋(FFPE)样本,以便获取临床结局。采用一种统计峰检测方法,将表达 或 (其具有重叠基因表达特征)的肿瘤与既不表达癌基因且呈现独特表型的一组肿瘤区分开来。 或 的表达与 和 基因的表达密切相关,这表明它们是ACC肿瘤中Myb蛋白的直接靶点。无监督层次聚类识别出一个亚组,该亚组约20%的患者总生存期极差(中位生存期不到30个月),且具有类似于胚胎干细胞的独特基因表达特征。这些结果为ACC患者分层及识别高风险、预后差的患者群体提供了一种策略,这些患者群体是个性化治疗的候选对象。